Delays to an Indian company's generic versions of three blockbuster drugs annually cost U.S. health-care payers millions of dollarsâ€”and preserve millions of dollars in revenue for the makers of the brand-name versions..  AstraZeneca PLC's heartburn drug Nexium is the most recent big drug to face delays to its generic version. Key patents on the U.K. company's "purple pill," which ranks among the world's best-selling prescription drugs, expired at the end of May, but manufacturing problems at India's Ranbaxy Laboratories...
  